ATCC Licenses CRISPR/Cas9 Technology from the Broad Institute

Meets untapped needs with release of new isogenic cell line

Jan 12, 2016, 09:38 ET from American Type Culture Collection

MANASSAS, Va., Jan. 12, 2016 /PRNewswire-USNewswire/ -- ATCC, the premier global biological materials resource and standards organization, announces today that it licensed CRISPR/Cas9 gene editing technology from the Broad Institute of MIT and Harvard.  ATCC plans to use the gene editing technology to develop a portfolio of new products and services to support basic and translational research.

CRISPR gene editing allows for precise genetic modifications. This capability allows researchers to create more relevant and predictable in vitro disease models, which will enable a greater level of success in drug discovery, development, and screening.

"The rapid growth of CRISPR/Cas9 applications provides a perfect environment for ATCC to leverage our comprehensive portfolio of cells, microorganisms, and services to meet the unmet demands of global researchers to support their scientific discoveries.  Licensing the CRISPR/Cas9 technology from the Broad Institute allows ATCC scientists to unlock the full potential of our unique portfolio for creating standards for basic and translational research," stated Mindy Goldsborough, Ph.D., Vice President & General Manger, ATCC Cell Systems.  "We will build on the high quality and standards that researchers have expected from ATCC over the past 90 years."

The first ATCC product developed using the licensed technology is the EML4-ALK Fusion-A549 Isogenic Cell Line (ATCC® CCL-185IG™). This cell line was derived from the parental A549 non-small cell lung cancer cell line, which is known as a work horse for in vitro and in vivo lung cancer research. The EML4-ALK Fusion mutation is critical for drug discovery and molecular diagnostics of non-small cell lung cancer.  EML4-ALK Fusion-A549 Isogenic Cell Line has been intensively validated on the genomic, transcript, and protein level, and is otherwise identical to the parental line. This isogenic cell line is more sensitive to ALK inhibitor crizotinib when compared to A549, and serves as a vital model to study cell signaling pathways in cancer as well as in drug screening. EML4-ALK Fusion-A549 Isogenic Cell Line is available at

About ATCC

ATCC collaborates with and supports the scientific community with industry-standard products and innovative solutions. With the world's largest and most diverse collection of human and animal cell lines, molecular genomic tools, microorganisms, biological products, and standards ATCC is a trusted biological resource for the worldwide research community. Together, the people of ATCC share in its mission to acquire, authenticate, preserve, develop, and distribute biological materials and information for the advancement of scientific knowledge. Founded in 1925, ATCC is a non-profit organization with headquarters in Manassas, VA. Discover more at

Logo -


SOURCE American Type Culture Collection